Results 41 to 50 of about 1,036,342 (307)

A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types

Cancers, 2022
Simple Summary Many cancer drugs are cytotoxic, which means that they kill cancer cells effectively but are also toxic to normal cells. To overcome this problem, we designed a novel compound, VIP236, which consists of three components.
H. Lerchen, B. Stelte-Ludwig, C. Kopitz, M. Héroult, D. Zubov, Joerg Willuda, T. Schlange, Antje Kahnert, H. Wong, R. Izumi, A. Hamdy   +10 more
semanticscholar   +1 more source

Antibody–drug conjugates: Recent advances in linker chemistry

Acta Pharmaceutica Sinica B, 2021
Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs.
Zheng Su, Dian Xiao, Fei Xie, Lianqi Liu, Yanming Wang, Shiyong Fan, Xinbo Zhou, Song Li   +7 more
doaj   +1 more source

Fibroblast Activation Protein triggers release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors.

Clinical Cancer Research, 2022
PURPOSE Small Molecule-Drug Conjugates (SMDCs) are modular anti-cancer pro-drugs that include a tumor-targeting small organic ligand, a cleavable linker and a potent cytotoxic agent.
Aureliano Zana, A. Galbiati, Ettore Gilardoni, M. Bocci, J. Millul, Theo Sturm, R. Stucchi, Abdullah Elsayed, Lisa Nadal, Martina Cirillo, W. Roll, L. Stegger, Inga Asmus, Philipp Backhaus, Michael Schäfers, D. Neri, S. Cazzamalli   +16 more
semanticscholar   +1 more source

Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

Oncology Report, 2022
Targeted anticancer therapeutics offer the advantage of reducing cytotoxic side effects to normal cells by directing the cytotoxic payload selectively to cancer cells.
Tian-Qi Xu, Yongsheng Liu, A. Schulga, E. Konovalova, S. Deyev, V. Tolmachev, A. Vorobyeva   +6 more
semanticscholar   +1 more source

Linker Architectures as Steric Auxiliaries for Altering Enzyme-Mediated Payload Release from Bioconjugates.

Bioconjugate chemistry, 2021
Protease-activated prodrugs leverage the increased activity of proteases in the tumor microenvironment and the tight regulation in healthy tissues to provide selective activation of cytotoxins in the tumor while minimizing toxicity to normal tissues. One
M. Giese, P. D. Davis, R. Woodman, G. Hermanson, A. Pokora, Melissa Vermillion   +5 more
semanticscholar   +1 more source

Effects of crosstalk in WDM optical label switching networks due to wavelength switching of a tunable laser [PDF]

, 2006
rosstalk caused by switching events in fast tunable lasers in an optical label switching (OLS) system is investigated for the first time. A wavelength-division-multiplexed OLS system based on subcarrier multiplexed labels is presented which employs a 40 ...
Barry, Liam P., Smyth, Frank, Cotter, D., Ellis, A.D., Kaszubowska-Anandarajah, Aleksandra, Mishra, A.K., Connolly, Eoin M.   +6 more
core   +2 more sources

HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers

Cancer Discovery, 2020
Amplification and oncogenic mutations of ERBB2, the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather than its overexpression, are ...
Bob T. Li, F. Michelini, S. Misale, E. Cocco, L. Baldino, Yan-Yan Cai, Sophie G. Shifman, H. Tu, Mackenzie L Myers, Chongrui Xu, Marissa S. Mattar, I. Khodos, M. Little, B. Qeriqi, G. Weitsman, Clare J. Wilhem, A. Lalani, I. Diala, R. Freedman, N. Lin, D. Solit, M. Berger, P. Barber, T. Ng, M. Offin, J. Isbell, David R. Jones, H. Yu, S. Thyparambil, W. Liao, A. Bhalkikar, F. Cecchi, D. Hyman, Jason S. Lewis, Darren J Buonocore, A. Ho, V. Makker, J. Reis-Filho, P. Razavi, M. Arcila, M. Kris, J. Poirier, R. Shen, J. Tsurutani, G. Ulaner, E. de Stanchina, N. Rosen, C. Rudin, M. Scaltriti   +48 more
semanticscholar   +1 more source

Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions

Pharmacological Research
Drug conjugates are obtained from tumor-located vectors connected to cytotoxic agents via linkers, which are designed to deliver hyper-toxic payloads directly to targeted cancer cells.
Cuiping Li, Kourong Shi, Siyuan Zhao, Juan Liu, Qiaoli Zhai, Xiaoli Hou, Jie Xu, Xinyu Wang, Jiahui Liu, Xin Wu, Wei Fan   +10 more
doaj   +1 more source

Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells

OncoImmunology, 2019
Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20–40% of patients to generate anti-tumor immune responses.
Maxine Bauzon, Penelope M. Drake, Robyn M. Barfield, Brandon M. Cornali, Igor Rupniewski, David Rabuka   +5 more
doaj   +1 more source

Antibody–drug conjugate: a newly developed biological missile for tumor treatment

Frontiers in Oncology
Antibody–drug conjugates (ADCs) represent one of the most advanced drug configurations under current research, primarily composed of a monoclonal antibody (mAb), a highly potent cytotoxic payload, and a linker that connects the drug to the antibody.
Zhuoran Tang, Yanchun Xie, Yanping Zeng
doaj   +1 more source